Abstract: Compositions, kits, and methods of use of branched poly(ethylenimine) (BPEI) compounds, including polyethylene glycol (PEG)-branched poly(ethylenimine) conjugates (PEG-BPEI) for treatment of diseases, bacterial infections, bacterial biofilms, and conditions associated with inflammation, including wounds.

Abstract: Compositions of ?-lactam antibiotics and branched poly(ethylenimine) (BPEI), and ?-lactam antibiotics and potentiating compounds of polyethylene glycol (PEG)-BPEI conjugates, and methods of their use to treat infections and to remove bacterial biofilms from surfaces of devices and wounds. The BPEI and PEG-BPEI conjugates potentiate the activity of the ?-lactam antibiotics so the compositions have synergistic effects against various Gram-positive bacteria. For example, the compositions can be used to treat Gram-positive bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-resistant Staphylococcus epidermidis (MRSE), that have developed resistance against most ?-lactam antibiotics. The BPEI and PEG-BPEI conjugates result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as ?-lactam antibiotics.

Abstract: The present disclosure describes compositions comprising ?-lactam antibiotics and branched polyethylenimines (BPEI), having efficacy against various Gram-positive bacteria, for example Gram-positive bacteria having resistance against ?-lactam antibiotics. The compositions result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as cephem ?-lactam antibiotics.

Abstract: The present disclosure describes compositions comprising ?-lactam antibiotics and branched polyethylenimines (BPEI), having efficacy against various Gram-positive bacteria, for example Gram-positive bacteria having resistance against ?-lactam antibiotics, one non-limiting example of which is Methicillin-resistant Staphylococcus aureus (MRSA). The compositions result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as ?-lactam antibiotics.

Abstract: The present disclosure describes compositions comprising ?-lactam antibiotics and branched polyethylenimines (BPEI), having efficacy against various Gram-positive bacteria, for example Gram-positive bacteria having resistance against ?-lactam antibiotics, one non-limiting example of which is Methicillin-resistant Staphylococcus aureus (MRSA). The compositions result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as ?-lactam antibiotics.

Abstract: The present disclosure describes compositions comprising ?-lactam antibiotics and branched poly-ethylenimines (BPEI), having efficacy against various Gram-positive bacteria, for example Gram-positive bacteria having resistance against ?lactam antibiotics, one non-limiting example of which is Methicillin-resistant Staphylococcus aureus (MRSA). The compositions result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as ?-lactam antibiotics.